Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levelsHELFRICH, Barbara A; RABEN, David; HIRSCH, Fred R et al.Clinical cancer research. 2006, Vol 12, Num 23, pp 7117-7125, issn 1078-0432, 9 p.Article

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancerRABEN, David; HELFRICH, Barbara A; CHAN, Dan et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 37-46, issn 0093-7754, SUP4Article

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer HistologiesWYNES, Murry W; HINZ, Trista K; DZIADZIUSZKO, Rafal et al.Clinical cancer research (Print). 2014, Vol 20, Num 12, pp 3299-3309, issn 1078-0432, 11 p.Article

Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR InhibitionCASAS-SELVES, Matias; KIM, Jihye; DEGREGORI, James et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 16, pp 4154-4164, issn 0008-5472, 11 p.Article

Epidermal growth factor receptor family in lung cancer and premalignancyFRANKLIN, Wilbur A; VEVE, Robert; HIRSCH, Fred R et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 3-14, issn 0093-7754, SUP4Article